Direct acting antivirals (DAAs) stabilize or improve liver function in the majority of patientswith HCV cirrhosis. Hepatic decompensation is the main driver of death of patients with early,successfully treated HCC superimposed to cirrhosis. Treatment with DAAs could improve theprognosis of these subjects, independently from the subsequent course of HCC, if the efficacy inobtaining viral clearance is as high as in patients without a history of HCC, and if the risk of HCCrecurrence is unaffected. When dealing with HCC patients, DAAs can be indicated in two differentsettings: a) subjects in which HCC has been already successfully treated (“cured” HCC), or b) subjectswhose HCC is still untreated or untreatable (“active” HCC). While there are abundant data on“cured” HCC, evidence supporting treatment decisions in patients with “active” HCC is at best scarceand controversial, since these patients as well as patients with HCC listed for liver transplantation(LT) are usually excluded from treatment.
|Numero di pagine||9|
|Stato di pubblicazione||Published - 2018|
All Science Journal Classification (ASJC) codes